Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs

Journal of Veterinary Internal Medicine

Volumn 20, Issue 5, 2006, Pages 1132-1135

  Bach, Jonathan F ^a,b   Rozanski, Elizabeth A ^a   MacGregor, John ^a,c   Betkowski, Jean M ^a   Rush, John E ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Dover Veterinary Hospital   (United States)

Author keywords

Collapse; Cor pulmonale; Hypoxemia; Pulmonary arterial pressure; Syncope; Viagra

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; SILDENAFIL; VASODILATOR AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; FEMALE; MALE; PATHOLOGY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY;

ANIMALS; DOG DISEASES; DOGS; FEMALE; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RETROSPECTIVE STUDIES; VASODILATOR AGENTS;

CANIS FAMILIARIS; SYNCOPE;

EID: 33750340615     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[1132:REOSCA]2.0.CO;2     Document Type: Article

References (19)

1. Johnson L, Boon J, Orton C. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Int Med 1999;13:440-447.
2. MacDonald KA, Johnson LR. Pulmonary hypertension and pulmonary thromboembolism. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine, 6th ed. St. Louis, MO: Elsevier Saunders; 2005:1284-1288.
3. Johnson LR, Hamlin RL. Recognition at treatment of pulmonary hypertension. In: Bonagura JD, Kirk RW, eds. Kirk's Current Veterinary Therapy, 12th ed. Philadelphia, PA: WB Saunders; 1995:887-892.
4. Tilley LP, Goodwin JK. Manual of Canine and Feline Cardiology, 3rd ed. Philadelphia, PA: WB Saunders; 2001:128.
5. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
6. Rubin LR, Badesh DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
7. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. Circulation 2005;111:3274-3280.
8. Galié N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
9. Hon KL, Cheung KL, Siu KL, et al. Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol Neonate 2005;88:109-112.
10. Lee AJ, Chiao TB, Tsang MP. Sildenafil for pulmonary hypertension. Ann Pharmacother 2005;39:869-884.
11. Karatza AA, Bush A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005;100:267-273.
12. Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide and iloprost in primary pulmonary hypertension. Chest 2004;125:580-586.
13. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation 2002;105:2398-2403.
14. Lepore FL, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension. Chest 2005;127:1647-1653.
15. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999;29:297-310.
16. Proulx J, Dhupa N. Sodium nitroprusside: Uses and precautions. In: Bonadura JD, ed. Kirk's Current Veterinary Therapy, 13th ed. Philadelphia, PA: WB Saunders; 2000:194-197.
17. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855-1860.
18. Corbin JD, Beasley A, Blount MA, et al. High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Comm 2005;334:930-938.
19. Ghofrani HA, Voswinckel R, Reichenberger R, et al. Differences in hemodynamic and oxygenation response to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2004;44:1488-1496.